



## Alpine Immune Sciences Announces Participation in September Investor Conferences

September 7, 2021

SEATTLE--(BUSINESS WIRE)--Sep. 7, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that members of its management team will present at the following investor conferences in September 2021:

**H.C. Wainwright 23<sup>rd</sup> Annual Global Investment Conference**

Date: Monday, September 13, 2021

Time: Available on demand beginning 7:00 a.m. ET/4:00 a.m. PT

Event: Company Presentation

**Oppenheimer Fall Healthcare Summit**

Date: Monday, September 20, 2021

Time: 2:55 p.m. ET/11:55 a.m. PT

Event: Fireside Chat

**Cantor Global Healthcare Conference**

Date: Wednesday, September 29, 2021

Time: 2:00 p.m. ET/11:00 a.m. PT

Event: Company Presentation

Webcasts of the H.C. Wainwright, Oppenheimer, and Cantor presentations will be available online in the investor relations section of the company's website at <https://ir.alpineimmunesciences.com/events>. A replay of the presentations will be available on the company website for 90 days following the webcast.

### About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients' lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit [www.alpineimmunesciences.com](http://www.alpineimmunesciences.com). Follow [@AlpineImmuneSci](https://twitter.com/AlpineImmuneSci) on [Twitter](#) and [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210907005744/en/): <https://www.businesswire.com/news/home/20210907005744/en/>

### Investor Relations

Alex Sharif

Director, Investor Relations and Corporate Development

Alpine Immune Sciences, Inc.

206-788-4545

[ir@alpineimmunesciences.com](mailto:ir@alpineimmunesciences.com)

### Media Relations

Kelli Perkins

Red House

[Kelli@redhousecomms.com](mailto:Kelli@redhousecomms.com)

Source: Alpine Immune Sciences, Inc.